Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
ExCulture logo — More sustainable, ethical, animal-free heparin alternative

ExCulture

More sustainable, ethical, animal-free heparin alternative

Founded 2022 The Netherlands The Netherlands 3 employees Total: $350.00K Biotechnology, Pharmaceutical +1

General Information

Company Name ExCulture
Founded Year 2022
Location The Netherlands The Netherlands
Employees 3
Industries Biotechnology, Pharmaceutical, Sustainability
Business Model B2B, B2D, API
Revenue Model Licensing, Product Sales, Service Fee
Offices as of Sep 2026
Delft, The Netherlands
Social

BounceWatch is an independent company data service, not affiliated with ExCulture. To contact ExCulture, visit exculturebiotech.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ExCulture compare?

A PDF of ExCulture and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ExCulture soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ExCulture

ExCulture is an innovative biotech startup that specializes in applying a mixed-culture fermentation bioprocess for the production of pharmaceuticals. Founded in 2022, the company is at the forefront of leveraging advanced biotechnological processes to enhance drug production efficiencies and scalability, addressing a significant need in the pharmaceutical industry.

Despite not having a designated headquarters or specific industry classifications yet, ExCulture has quickly captured the attention of prominent investors. On 01 June 2024, the company secured early venture capital investment from Capricorn Partners and Tech Transfer, indicating strong confidence in its business model and technological potential.

As ExCulture navigates the competitive biotech landscape, its commitment to cutting-edge fermentation techniques makes it a noteworthy contender for investors seeking transformative prospects in the pharmaceutical production domain.

Business keywords: Mixed-culture fermentation, Pharmaceutical production, Natural fermentation, Life-saving pharmaceuticals, Animal-free bioprocessing, Carbon source optimization, Glycosaminoglycans, Heparin production, Biopharmaceuticals, Innovative fermentation techniques, R&D in bioprocess technology, Sustainable pharmaceutical manufacturing

Services & Products

Development of animal-free heparin substitute
Biopharmaceutical production using mixed culture fermentation

Target Customers

Pharmaceutical companies Healthcare providers Biotech researchers Biopharmaceutical manufacturers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC Undisclosed 2
Capricorn Partners, Tech transfer
01 Jun 2024
Seed €350.00K 1
UNIIQ - Finance for the Future
UNIIQ - Finance for the Future
01 Dec 2023
Support Program Undisclosed 1
YES!Delft
01 Dec 2022
Spinout Undisclosed 2
TU Delft Delft Enterprises B.V.
TU Delft, Delft Enterprises B.V.
01 Jan 2022

ExCulture Alternatives & Competitors

View All Alternatives
ExCulture vs
Intract Pharma
Intract Pharma United Kingdom

Transforming Patient Care by Replacing Injections with Safer, More Effective Therapeutics Given Oral...

Seed
14 employees
Biotechnology, Life Sciences
ExCulture vs
Future Cow Technologies
Future Cow Technologies Brazil

We're on a mission to make milk, without cows.

Seed
5 employees
Biotechnology, Food and Beverage
ExCulture vs
Cullgen Inc.
Cullgen Inc. United States

Powering protein degradation for tomorrow's medicines

Acquired
27 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About ExCulture

More sustainable, ethical, animal-free heparin alternative
ExCulture was founded in 2022.
ExCulture is headquartered in The Netherlands. As of Sep 2026, it also has offices in Delft, The Netherlands.
ExCulture operates in Biotechnology, Pharmaceutical and Sustainability. Its work centres on Mixed-culture fermentation, Pharmaceutical production, Natural fermentation and Life-saving pharmaceuticals. Its customers include Pharmaceutical companies, Healthcare providers and Biotech researchers.
ExCulture has a B2B, B2D and API business model. Its revenue comes from Licensing, Product Sales and Service Fee.
ExCulture has approximately 3 employees.
ExCulture has completed 4 funding rounds, raising a total of $350.00K.
ExCulture offers: Development of animal-free heparin substitute, Biopharmaceutical production using mixed culture fermentation.
Top alternatives and competitors to ExCulture include Intract Pharma, Future Cow Technologies, Cullgen Inc., Alchemab Therapeutics Ltd, Change Foods. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ExCulture and Intract Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ExCulture, https://bouncewatch.com/company/exculture, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes